查詢結果分析
相關文獻
- Vancomycin用於預防冠狀動脈繞道手術感染的角色:一個前瞻性研究
- 冠狀動脈繞道手術之手術部位感染危險因子之探討
- Surgical Treatment for Coronary Heart Disease Associated with Polycythemia Vera--A Case Report
- Minimally-Invasive, Direct Coronary Artery Bypass Grafting
- Postinfarction Ventricular Aneurysm: surgical Results of Aneurysmectomy and Concomitant Coronary Artery Bypass Grafting
- Coronary Artery Bypass Surgery in a 24-Year-Old Man: A Case Report and Review of Literature
- Acute Normovolemic Hemodilution in Coronary Artery Bypass Graft Surgery
- Coronary Artery Bypass Grafting on the Beating Heart Using the Octopus Method--A Case Report
- Radial Artery as an Arterial Graft Conduit for Myocardial Re-vascularization
- Coronary Artery Bypass Grafting without Extracorporeal Circulation in Octogenarians
頁籤選單縮合
題 名 | Vancomycin用於預防冠狀動脈繞道手術感染的角色:一個前瞻性研究=The Use of Vancomycin for the Surgical Prophylaxis in Coronary Artery Bypass Surgery: A Prospective Study |
---|---|
作 者 | 陳郁慧; 莊銀清; 湯宏仁; 鄭伯智; | 書刊名 | 院內感染控制雜誌 |
卷 期 | 12:6 2002.12[民91.12] |
頁 次 | 頁345-354 |
分類號 | 418.281 |
關鍵詞 | 冠狀動脈繞道手術; 外科預防性抗生素; Coronary artery bypass graft; CABG; Surgical prophylactic antibiotic; |
語 文 | 中文(Chinese) |
中文摘要 | 近年來對 oxacillin 抗藥性的 Staphylococcus aureus(ORSA)或Staphylococcus epidermidis(ORSE)在各大醫學中心的院內感染菌株所佔百分比愈來愈高,約50-82.2%,而本院近三年來院內感染菌株之ORSA及 ORSE 也佔73%及91%,因此 vanoomycin 用於心臟外科手術的預防性投與屢見不鮮。為了評估 vancomycin 在預防冠狀動脈繞道手術 (CABG)感染的角色,從2001年一月至三月所有病人採用 cefuroxime、qentam-icin 及 vancomycin 作術前預防(A組),而2001年四月至七月則採用cefuroxime 及 gentamicin 作術前預防(B組);記錄並比較兩組病人之年齡、性別、住院天數、手術時間、疾病嚴重度分類、院內感染部位、菌種、各項危險因子、術後合併症、預後、抗生素花費、總住院費用。結果顯示兩組病人(A組37人,B組32人)之基本資料及及疾病嚴重度沒有差異,且兩組住院天數、術後合併症、院內感染及預後亦沒有差異,惟A組抗生素耗費 7,528±2,749元,B組4,742±2,266元(Mann-Whitney U test 檢定法 p<0.001)。結論是,使用 vancomycin 與否,並不影響CABG 的手術後感染,但增加了抗生素的藥費。由此研究顯示,在目前的臨床狀況下,並不需要 vancomycin 來預防 CABG 的術後感染。(感控雜誌2002;12:345-54) |
英文摘要 | From 50 to 82.2% of the nosocomial isolates of Staphyloccus aureus and Staphylococcus epidermidis in major hospitals in Taiwan are oxacillin-resis-rant, and were 73% and 91% at our hospital. Glycopeptides are now being used frequently for the surgical prophylaxis. To assess the role of the vancomycln in the prophylaxis in coronary artery bypass surgery (CABG), we conducted a prospective study comparing two regimens of antibiotics: one with cefuroxime4-gentamicin, and the other, cefuroxime+gentamicin+van- comyein. From January to July, 2000, 32 patients received the first regimen and 37 patients received the second. The two groups of patients were comparable in all potential risk factors. The result indicates that there were no statistical differences in the median hospital stay (11 days vs. 13 days; p=0,134), and episodes of post-operative infections (1 vs. 4; p=0.235). There was a significant difference in the cost of antibiotics between the two groups (NT 4,629 vs. NT 7,020; p=0,001). Our data suggest that the addition of vancomycin provides no extra benefit over cefuroxime + gentamicin in the surgical prophylaxis for the CABG. We suggest that vancomycin is not needed for the surgical prophylaxis in CABG. (Nosocom Infect Control d 2002;12: 345-54) |
本系統中英文摘要資訊取自各篇刊載內容。